CN119156222A - 治疗剂 - Google Patents

治疗剂 Download PDF

Info

Publication number
CN119156222A
CN119156222A CN202380030569.XA CN202380030569A CN119156222A CN 119156222 A CN119156222 A CN 119156222A CN 202380030569 A CN202380030569 A CN 202380030569A CN 119156222 A CN119156222 A CN 119156222A
Authority
CN
China
Prior art keywords
agent
inhibitor
protein
nlpd
pyelonephritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380030569.XA
Other languages
English (en)
Chinese (zh)
Inventor
凯瑟琳娜·斯万伯格
伊内斯·安比特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saiakt Immunopharmaceutical Co ltd
Original Assignee
Saiakt Immunopharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saiakt Immunopharmaceutical Co ltd filed Critical Saiakt Immunopharmaceutical Co ltd
Publication of CN119156222A publication Critical patent/CN119156222A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202380030569.XA 2022-01-28 2023-01-27 治疗剂 Pending CN119156222A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2201139.9 2022-01-28
GBGB2201139.9A GB202201139D0 (en) 2022-01-28 2022-01-28 Therapeutic agent
PCT/EP2023/052076 WO2023144341A1 (en) 2022-01-28 2023-01-27 Therapeutic agent

Publications (1)

Publication Number Publication Date
CN119156222A true CN119156222A (zh) 2024-12-17

Family

ID=80621245

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380030569.XA Pending CN119156222A (zh) 2022-01-28 2023-01-27 治疗剂

Country Status (7)

Country Link
US (1) US20250241990A1 (https=)
EP (1) EP4469153A1 (https=)
JP (1) JP2025503251A (https=)
CN (1) CN119156222A (https=)
AU (1) AU2023213106A1 (https=)
GB (1) GB202201139D0 (https=)
WO (1) WO2023144341A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119936405A (zh) * 2025-01-23 2025-05-06 上海市重大传染病和生物安全研究院 血浆IL-1Ra作为生物标志物在儿童脓毒症诊断和预后中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA761627B (en) 1976-03-16 1978-01-25 C Friedmann Improvements in or relating to the treatment of arthritis
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US8153166B2 (en) * 2006-06-08 2012-04-10 Chih-Hsiung Lin Composition for prophylaxis or treatment of urinary system infection and method thereof
GB201617548D0 (en) * 2016-10-17 2016-11-30 Linnane Pharma Ab Novel biological factor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119936405A (zh) * 2025-01-23 2025-05-06 上海市重大传染病和生物安全研究院 血浆IL-1Ra作为生物标志物在儿童脓毒症诊断和预后中的应用

Also Published As

Publication number Publication date
JP2025503251A (ja) 2025-01-30
WO2023144341A1 (en) 2023-08-03
GB202201139D0 (en) 2022-03-16
AU2023213106A1 (en) 2024-09-12
US20250241990A1 (en) 2025-07-31
EP4469153A1 (en) 2024-12-04

Similar Documents

Publication Publication Date Title
US11241487B2 (en) Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7)-bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders
JP6416627B2 (ja) ペプチドおよびその使用法
JP2002220342A (ja) インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
AU2012228769A1 (en) Antagonists of the interleukin- 1 receptor
CN116323649A (zh) 膜联蛋白a1 n-末端肽的制剂和方法
CN117597357A (zh) 白细胞介素-22的治疗性衍生物
CN119156222A (zh) 治疗剂
CN103391786B (zh) 作为抗糖尿病肽的载脂蛋白a-iv
US20250352624A1 (en) Superoxide dismutase and uses thereof for preventing or treating dry eye syndrome
EP3515479A1 (en) Treatment and/or prevention of sepsis
JP5635779B2 (ja) Ｓｔｘ毒性阻害ペプチドおよびＳｔｘに起因する疾患の治療薬
US20150018268A1 (en) Multivalent synthetic compounds as antibiotic treatment
CN110769843A (zh) C5a受体激动剂肽的盐酸盐
KR20220051418A (ko) 근위축성 측삭 경화증 치료제
CN118767111A (zh) 一种抗耐药菌活性肽Hydrostatin-AMP3在治疗细菌性脓毒症中的应用
JP5982394B2 (ja) ＭＭＰ基質で連結したβｉｇ−ｈ３断片ペプチド及びそのリウマチ性関節炎予防及び治療用途
JP2002505081A (ja) セリンプロテアーゼ阻害剤
US20250235506A1 (en) Chimeric il-10/carrier constructs for treatment of pouchitis and methods of use
JP7813293B2 (ja) コロナウイルス治療法
WO2007060440A2 (en) The use of peptides in anti-ulcer therapy
JP6578546B2 (ja) Ｌｔ阻害４価ペプチドおよびｅｔｅｃ感染症治療薬
JP7792727B2 (ja) アミロイド前駆体タンパク質に対する阻害活性を有するペプチドおよびその用途
WO2007118431A1 (zh) Trap 蛋白自身作为活性成分在制备治疗金黄色葡萄球菌感染的药物中的应用
WO2006063596A2 (en) A composition comprising pp for the treatment of gastrointestinal disorders
CN120504723A (zh) 一种寡肽修饰物及其在制备治疗和/或改善肾脏疾病的药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination